key: cord-1019543-r9dyt0n5
authors: da Silva, Clarisse Salgado Benvindo; Thaler, Melissa; Tas, Ali; Ogando, Natacha S.; Bredenbeek, Peter J.; Ninaber, Dennis K.; Wang, Ying; Hiemstra, Pieter S.; Snijder, Eric J.; van Hemert, Martijn J.
title: Suramin inhibits SARS-CoV-2 infection in cell culture by interfering with early steps of the replication cycle
date: 2020-05-07
journal: bioRxiv
DOI: 10.1101/2020.05.06.081968
sha: f0473dd5630577e97bd3bd688f697c934003ec34
doc_id: 1019543
cord_uid: r9dyt0n5

The SARS-CoV-2 pandemic that originated from Wuhan, China, in December 2019 has impacted public health, society and economy and the daily lives of billions of people in an unprecedented manner. There are currently no specific registered antiviral drugs to treat or prevent SARS-CoV-2 infections. Therefore, drug repurposing would be the fastest route to provide at least a temporary solution while better, more specific drugs are being developed. Here we demonstrate that the antiparasitic drug suramin inhibits SARS-CoV-2 replication, protecting Vero E6 cells with an EC50 of ∼20 µM, which is well below the maximum attainable level in human serum. Suramin also decreased the viral load by 2-3 logs when Vero E6 cells or cells of a human lung epithelial cell line (Calu-3) were treated. Time of addition and plaque reduction assays showed that suramin acts on early steps of the replication cycle, possibly preventing entry of the virus. In a primary human airway epithelial cell culture model, suramin also inhibited the progression of infection. The results of our preclinical study warrant further investigation and suggest it is worth evaluating whether suramin provides any benefit for COVID-19 patients, which obviously requires well-designed, properly controlled randomized clinical trials.

containing the RT-qPCR target sequences was used for absolute quantification. A RT-qPCR program of 163 5 min at 50 °C and 20 s at 95 °C, followed by 45 cycles of 5 s at 95 °C and 30 s at 60 °C, was performed 164 on a CFX384 Touch™ Real-Time PCR Detection System (Bio-Rad). 165 166

Cytopathic effect (CPE) reduction assay 167 CPE reduction assays were performed as described (22). Briefly, Vero E6 cells were seeded in 96-well 168 cell culture plates at a density of 10 4 cells per well. Cells were incubated with 1.7-fold serial dilutions 169 of suramin starting from a concentration of 120 µM. Subsequently, cells were either mock-infected 170

(analysis of cytotoxicity of the compound) or were infected with 300 PFU of virus per well (MOI of 171 0.015) in a total volume of 150 µl of medium. Cell viability was assessed three days post-infection by 172

MTS assay using the CellTiter 96® Aqueous Non-Radioactive Cell Proliferation kit (Promega) and 173 absorption was measured at 495 nm with an EnVision Multilabel Plate Reader (PerkinElmer). The 50% 174 effective concentration (EC50), required to inhibit virus-induced cell death by 50%, and the 50% 175 cytotoxic concentration (CC50), that reduces the viability of uninfected cells to 50% of that of untreated 176 control cells, were determined using non-linear regression with GraphPad Prism v8.0. 177 178 Viral load reduction assays 179

Cells were seeded in 96-well cell culture plates at a density of 10 4 (Vero E6) or 6 x 10 4 (Calu-3) cells per 180 well in 100 µl culture medium. As control to determine the amount of residual virus after removal of 181 the inoculum and washing, cells in some wells were killed with 70% Ethanol (followed by washing with 182 PBS). Vero E6 and Calu-3 cells were incubated with 2-fold serial dilutions of a starting concentration 183

of 200 µM of suramin and subsequently infected with 2 x 10 4 PFU of SARS-CoV-2 (MOI of 1 on Vero E6 184 cells). For analysis of viral RNA, supernatant was harvested from Vero E6 cells at 16 h.p.i and from 185

Calu-3 cells at 21 h.p.i. Intracellular RNA was collected by lysing the cells in 150 µl Tripure reagent. 186

Analysis of viral progeny in supernatant from Calu-3 cells was performed by plaque assay on Vero E6 187 cells (17). Potential cytotoxicity of the compound was tested in parallel on uninfected cells using the 188 MTS assay (Promega) as described for the CPE reduction assay. 189 190

Entry inhibition plaque reduction assay 191

A day before infection Vero E6 cells were seeded in 6-well cell culture plates at a density of 3.5 x 10 5 192 cells per well in 2 ml medium. 10 -2 to 10 -5 -fold serial dilutions of a SARS-COV-2 stock were prepared in 193 medium containing 100, 50, 25, 12.5, 6.25 or 0 µM suramin. These were used as inoculum to infect 194 the Vero E6 cells in 6-well clusters. After 1 h at 37 o C, the inoculum was removed and cells were 195 incubated in Avicel-containing overlay medium without suramin for 3 days, after which they were 196 fixed with 3.7% formaldehyde, stained with crystal violet and plaques were counted (17). 197 198 Time of addition assay 199

Vero E6 cells were seeded in 24-well clusters at a density of 6 x 10 4 cells per well. The next day cells 200

were treated with 100 µM suramin during the time intervals indicated in Fig. 3 

Suramin inhibits SARS-CoV-2 replication in Vero E6 cells 222

To determine if suramin could protect cells from SARS-CoV-2 infection and to evaluate its toxicity, 223

Vero E6 cells were infected with SARS-CoV-2 and treated with serial dilutions of suramin in a CPE 224 reduction assay. Suramin protected infected cells from SARS-CoV-2-induced cell death in a dose-225 dependent manner, with an EC50 of 20 ± 2,7 µM (Fig. 1A) . In parallel, non-infected cells were treated 226

with the same concentrations of suramin in order to assess the compound's toxicity. No toxicity was 227 observed over the range of concentrations that was used in these antiviral assays. Only at 5 mM cell 228 viability dropped to 67%, resulting in a CC50 > 5 mM (15). Therefore, suramin inhibits SARS-CoV-2 with 229 a selectivity index (SI) higher than 250. 230

To more directly measure the inhibition of viral replication by suramin, viral load reduction assays 231

were performed. Vero E6 cells were infected with SARS-CoV-2 at an MOI of 1 and they were treated 232 with increasing concentrations of suramin. At 16 h.p.i., supernatant was harvested to determine the 233 viral load by quantifying the levels of extracellular viral RNA by RT-qPCR ( Fig 1B) . 

To assess the antiviral effect of suramin in a more relevant model, human lung epithelial cells (Calu-3)  255 were infected with 2 x 10 4 PFU of SARS-CoV-2 in the presence of 0-200 µM suramin for 1h. After 256 removal of the inoculum and washing of the cells, incubation was continued in medium with suramin 257 (0-200 µM) for 20 hours. At 21 h.p.i., RNA was isolated from cells and supernatant and the viral titer 258

in the supernatant was determined by plaque assay. We observed a strong dose-dependent reduction 259

in intracellular ( Fig with RT-qPCR reactions targeting the SARS-CoV-2 N protein gene (also detects subgenomic RNA), 264

although in that case absolute copy numbers -as expected-were higher than for genomic RNA (data 265 not shown). Plaque assays confirmed that treatment with 200 µM suramin led to an almost 3-log drop 266

in infectious progeny titers from infected-Calu-3 cells (Fig. 2C ). 267

Cytotoxicity assays performed in parallel in non-infected Calu-3 cells showed that suramin was slightly 268 more toxic to these cells than to Vero E6 cells, although cell viability remained above 80% even at the 269 highest dose tested (Fig. 2D ). Together these results suggest that suramin is a potent SARS-CoV-2 270

inhibitor with high selectivity, also in human lung cells. Suramin acts on the early steps of viral replication 293

To determine which step of viral replication is affected by suramin, we performed a time-of-addition 294 assay. Cells were infected with SARS-CoV-2 (MOI 1) and treated with 100 µM of suramin over different 295 time intervals, as schematically depicted in Figure 3A . Treatment was initiated 1 hour before infection 296 or at 0, 1, 2, 4, 6 or 8 h.p.i., and suramin remained present until 10 h.p.i., when supernatants were 297 harvested to determine viral load by RT-qPCR targeting the RdRp coding region. In one sample suramin 298 was only present for 60 min during the time of infection. After 1 hour, virus inoculum was removed 299

and cells were washed three times with PBS, followed by incubation in medium with or without 300

suramin. At 10 h.p.i., supernatant was collected to evaluate the levels of viral RNA (Fig. 3B ). When 301 suramin treatment was initiated 1 hour before (-1h) or at the time of infection (0h) a 2-log reduction 302 in viral RNA levels was observed. Treatments that started later than 1 hour post infection did not 303 inhibit viral replication, as viral RNA levels similar to the non-treated control were observed. 304

Treatment only during the infection (0-1h) resulted in the same 2-log reduction in viral RNA load as 305 the 0-10h treatment, indicating that suramin inhibits an early step of the replication cycle, likely viral 306 entry. 307

To confirm suramin's inhibitory effect on entry, we performed a plaque reduction assay, by infecting 308

Vero E6 cells with serial dilutions of SARS-CoV-2 in the presence of increasing concentrations of 309 suramin, which was only present during the one hour of infection. After infection, cells were washed 310 3 times with PBS and were incubated with overlay medium without suramin. After 3 days, cells were 311 fixed, stained and plaques were counted. Suramin caused a dose-dependent reduction in the number 312 of plaques and even at the lowest suramin concentration (12.5 µM) titers were already reduced by 313 almost one log (Fig. 3C) . These results suggest that suramin inhibits SARS-CoV-2 entry. in untreated cells, while at 48h a more than 1 log increase in viral RNA copies was observed. This is 339

indicative of (very modest) viral replication in PBS-treated cells. The cultures that were treated with 340 suramin displayed no increase in viral load in the supernatant, but rather even a slight decrease in 341 copy numbers, suggesting viral replication did not progress in treated cells. At 48 h.p.i. the supernatant 342 of suramin-treated cells showed 2-log lower SARS-CoV-2 released genome copy numbers than PBS-343 treated control cells (Fig. 4A) . The levels of intracellular viral RNA displayed the same trend, with a 344 decrease in viral RNA in suramin-treated samples compared to an increase in viral RNA in PBS-treated 345 samples (Fig. 4B) . A 1-log difference, from 10 6 to 10 5 copies per transwell was observed at 48 h.p.i. 346

between suramin-and PBS-treated cells (Fig. 4B ). The levels of the housekeeping gene, PGK1 remained 347 stable in all samples, suggesting the reduction in viral RNA copies was not due to cell death. Moreover, 348 cell viability measured by MTS assay (Fig. 4C) not provide much benefit to COVID-19 patients and could actually be dangerous due to possible side-380 effects. This leaves us currently empty-handed and in search for other approved drugs that might be 381

repurposed. As an already approved antiparasitic drug, suramin would be one of the candidates for 382 fast development of a treatment for COVID-19. Antiviral activity of suramin against RNA viruses was 383

reported earlier by us and several other groups (15, 29-31) and the compound was and is also being 384 evaluated in several clinical trials for other diseases, providing some evidence for its safety for 385 therapeutic use. However, suramin can also cause several side-effects, which caused previous HIV 386 trials with seriously ill patients to halt (32) and therefore caution is advised and it is crucial to conduct 387 well controlled randomized trials, before any conclusions on possible benefits for COVID-19 patients 388

can be drawn. Thus far, no studies have reported about a potential antiviral effect of suramin against 389

coronaviruses. 390

In this study we assessed the antiviral activity of suramin against the newly emerged SARS-CoV-2. 391

Suramin offered full protection against SARS-CoV-2-induced cell death in Vero E6 cells and inhibited 392 the virus with an EC 50 of 20 µM and a SI of >250 (Fig. 1) . Suramin treatment of infected Vero E6 cells 393 led to a reduction in extracellular viral RNA levels of up to 3 log. The highest concentration of 394

compound that was used proved harmless to the cells and also previously cytotoxicity was only 395 observed above 5 mM (15). Suramin also displayed antiviral efficacy in a human lung epithelial cell 396 line and we observed a >2 log reduction in infectious virus progeny in suramin-treated cells. 397 Suramin was previously described to have the potential to inhibit several stages of virus replication by 398 acting on different targets (15, 33) . To assess which step in the SARS-CoV-2 replication cycle is affected 399 by suramin treatment, we performed a time-of-addition assay. We observed that pre-treatment with 400 suramin as well as addition during the first hour of infection resulted in a marked decrease of viral 401 RNA in the supernatant, while treatments initiated after the first hour of infection showed no 402 significant effect on virus replication, suggesting that suramin inhibits binding or entry. In addition, 403 SARS-CoV-2 infectivity was decreased in plaque assays, when suramin was present only in the 404 inoculum during infection, concordant with an effect on the early stages of infection (Fig. 3) . This is in 405 agreement with other studies that also reported on the inhibition of virus binding or entry by suramin 406 (15, 30, 34) . Our data suggest that the antiviral effect of suramin is primarily due to inhibition of 407 binding and/or fusion. 408

Finally we evaluated the effect of suramin in a more relevant model of differentiated primary human 409 airway epithelial (HAE) cells cultured and infected at the physiologically relevant air-liquid interface. 410

We infected these cells with a relatively low dose of virus (estimated MOI of 0. Administration of 100 µM of suramin on the apical side of the HAE cells did not appear to cause 425 cytotoxic effects in our study (Fig. 4) containing samples needed to be diluted by a 100-fold to exclude interference with the plaque assay, 434 the limit of detection would be 100 pfu/ml. Even with this limit of detection, the supernatant collected 435 from suramin-treated HAE cells contains at least 100 times less virus than that from PBS-treated cells. 436

Much higher titers were obtained with HAE cultures from mixed donors than from single donors, but 437 the inhibitory effect of suramin was also observed with single donor cultures. Overall, despite the 438 modest level of infection in control cells, our results suggest that also in the HAE infection model, 439

suramin has an inhibitory effect on progression of the SARS-CoV-2 infection. 440

Our study demonstrates that suramin inhibits SARS-CoV-2 replication in various cell culture models 441 and at clinically achievable concentrations (after IV administration serum levels of >10x the EC50 could 442 be achieved). Due to its mode of action (inhibition of entry) treatment of patients with suramin might 443 require administration at an early stage, although it might also prevent spread of the virus in the lungs 444 of already symptomatic patients or could prevent spread from respiratory tract to other organs. It 445 might possibly even be used to prevent virus spreading in the nasopharynx, which appears to be the 446 first site of infection (39-41). Standard treatment with suramin is done by intravenous administration, 447 which would also be an option for seriously ill COVID-19 patients that are in intensive care, but is not 448 ideal for other patients. As a negatively charged compound, suramin binds to various proteins and is 449 poorly taken up by diffusion across the cell membrane, although it can be taken up by endocytosis 450

(33). This poor uptake of suramin into cells might not necessarily be a problem for the efficacy against 451 SARS-CoV-2, as it is expected to block the virus systemically and in the extracellular environment. 452

Hypothetically, suramin administration into the respiratory tract in an aerosolized form could be even 453 considered, although this requires new safety studies. 454

In conclusion, our preclinical study shows that suramin inhibits SARS-CoV-2 replication in cell culture, 455

likely by preventing entry. Suramin also appears to prevent progression of SARS-CoV-2 infection in a 456 human airway epithelial cell culture model. This is only the first step towards evaluating whether 457 suramin treatment could provide any benefit to COVID-19 patients. Further studies should carefully 458 evaluate different formulations, routes of administration, pharmacokinetics, and possible adverse 459 effects in cell culture and ex vivo models. Ultimately, the clinical benefits of suramin for the treatment 460

of COVID-19 patients should be evaluated in carefully performed and properly controlled clinical trials. 461 462 463

Outbreak of pneumonia of unknown etiology in Wuhan, 472 China: The mystery and the miracle

A pneumonia outbreak 510 dengue virus in a fluorescence-based high throughput assay format

Suramin inhibits chikungunya virus replication through 514 multiple mechanisms

Dynamic innate immune responses of human bronchial epithelial cells to severe acute 517 respiratory syndrome-associated coronavirus infection

6′-β-Fluoro-homoaristeromycin 520 and 6′-fluoro-homoneplanocin A are potent inhibitors of chikungunya virus replication 521 through their direct effect on the viral non-structural protein 1

TGF-β1 Impairs Vitamin D-524 Induced and Constitutive Airway Epithelial Host Defense Mechanisms

Aberrant epithelial differentiation 528 by cigarette smoke dysregulates respiratory host defence

6′-β-Fluoro-Homoaristeromycin 531 and 6′-Fluoro-Homoneplanocin A Are Potent Inhibitors of Chikungunya Virus Replication 532 through Their Direct Effect on Viral Nonstructural Protein 1

Detection of 2019 novel coronavirus (2019-nCoV) by real-537 time RT-PCR. Euro surveillance : bulletin Europeen sur les maladies transmissibles = 538

Characterization of Synthetic Chikungunya Viruses Based on the Consensus 541 Sequence of Recent E1-226V Isolates

Broad-spectrum 545 antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses

An orally bioavailable 550 broad-spectrum antiviral inhibits SARS-CoV-2 in human airway epithelial cell cultures and 551 multiple coronaviruses in mice

Severe acute respiratory 553 syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in 554 viral spread in the conducting airways of the lungs

Remdesivir 556 and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in 557 vitro

of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19

No evidence of rapid antiviral clearance or clinical benefit with the combination of 566 hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

Polysulfonate suramin inhibits Zika virus 569 infection

Dengue 571 virus infectivity depends on envelope protein binding to target cell heparan sulfate

Suramin: A potent inhibitor of the reverse transcriptase of RNA tumor 574 viruses

Lack of response to suramin in patients with AIDS and AIDS-related 577 complex

100 Years of Suramin

Suramin Inhibits 580 Chikungunya Virus Entry and Transmission

Airway and alveolar epithelial cells in culture

Human Nasal and Tracheo-Bronchial Respiratory Epithelial Cell 584

Epithelial Cell Culture Protocols: Second 585 Edition

SARS-CoV-2 Cell 588 Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease 589 Inhibitor

A SARS-like cluster of circulating bat coronaviruses shows potential for human 593 emergence

Clinical and virological data of the first cases of COVID-19 in 598 Europe: a case series

Comparative pathogenesis of 604 COVID-19, MERS, and SARS in a nonhuman primate model

Virological assessment of hospitalized patients 609 with COVID-2019